Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant serplulimab plus S-1 and oxaliplatin for locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2300069000Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: complete pathological response and complete clinical response. Started Mar 2023; status: recruiting.
02
Drugs
serplulimabtegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300069000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069000.